Navigation Links
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Date:12/2/2008

SKOKIE, Ill., Dec. 2 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints. HZT-501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (gastric and/or duodenal) ulcers in patients with mild-to-moderate pain when compared to ibuprofen alone.

NSAIDs such as ibuprofen are among the most widely used drugs in the world. However, NSAIDs are associated with a range of adverse side effects, which primarily affect the gastrointestinal (GI) tract. Up to 30 percent of patients taking NSAIDs experience gastrointestinal ulcers and a greater percent suffer from upper GI symptoms (i.e., dyspepsia, heartburn).

"NSAIDs, while highly effective in treating pain and inflammation, often lead to serious safety concerns, including significant gastrointestinal damage," said Timothy P. Walbert, president and chief executive officer, Horizon Therapeutics. "We are committed to bringing this much needed treatment to physicians and patients as quickly as possible and plan on submitting these strong HZT-501 Phase 3 results to U.S. and European regulatory authorities in 2009."

REDUCE-1 and REDUCE-2 Trial Design and Results

The Registration Endoscopic Study to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Study (REDUCE-1 and REDUCE-2) were two randomized, double-blind, controlled trials that enrolled more than 1,500 patients in the United States. The primary efficacy objective of REDUCE-1 was to evaluate HZT-501 in reducing the proportion of patients who develop endoscopically diagnosed gastric ulcers during the 24-week treatment pe
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
2. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
3. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
4. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
5. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
6. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
9. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
10. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
11. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  eRelevance Corporation ( www.erelevancecorp.com ), a ... it has completed integration with Nextech, a popular ... and Dermatology practices. "Integration allows our ... practices using Nextech," stated Bob Fabbio , ... from the EMR we are able to automatically ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
(Date:8/22/2014)... (PRWEB) August 22, 2014 The regional ... Toyota Indiana is on the grow again. ... jobs by summer 2016 to boost production of the ... bring Toyota Indiana’s overall investment to $4 billion. This ... America while providing additional flexibility to adjust its product ...
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... protein 11 (BIM) deletion in advanced non-small cell ... free survival (PFS) in epidermal growth factor receptor ... Asian patients. Also, BIM deletion independently predicts overall ... BIM protein can activate the programmed cell death ... BIM deletion has been detected in 12.8% of ...
(Date:8/22/2014)... Restore My Vision Today , a ... to help people discover how they can get rid ... instead improving their eyesight naturally has caught the attention ... “There’s a reason why the glasses and contacts industry ... people just assume that it’s their only option to ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... LLC, is proud to announce the latest benefits and features on ... ... -- Healthy Directions, LLC, is proud to announce the latest benefits ... premium quality, doctor-formulated products that address a wide range of health ...
... levels of psychological distress than those who are more ... European Society for Medical Oncology,s Symposium on Cancer and ... a common problem in cancer. It is estimated that ... weight loss and malnutrition during the course of their ...
... is needed is a new classification system and an overall standardization ... neurotrauma expert Geoff Manley, MD, PhD, professor of neurological surgery, co-director ... neurotrauma at UCSF-affiliated San Francisco General Hospital. , ... ...
... and cancer plays a major role in this disparity. African ... present at a later, deadlier stage; and they have poorer ... what extent are each of these three factors responsible for ... in Journal of General Internal Medicine Feb. 18, ...
... 17, 2009, the first of two effective dates in ... goes into effect. This final rule adopts Accredited ... and National Council for Prescription Drug Programs (NCPDP) Versions ... Compliance with these standards is mandatory by January 1, ...
... key to treatment, scientists say , , FRIDAY, March 20 ... an important role in the severe lung damage suffered ... Their findings may open up new targets for treatment ... United States. , "Cystic fibrosis patients have a problem ...
Cached Medicine News:Health News:Healthylivingnetwork.com Announces Web Site Enhancements and Additional Product Offerings 2Health News:Healthylivingnetwork.com Announces Web Site Enhancements and Additional Product Offerings 3Health News:Focus on treating malnutrition in cancer patients, researchers say 2Health News:Traumatic Brain Injury: UCSF Neurosurgeon Calls For More Research, Improved Treatment Standard 2Health News:Traumatic Brain Injury: UCSF Neurosurgeon Calls For More Research, Improved Treatment Standard 3Health News:Study quantifies racial disparities in cancer mortality rates between blacks and whites 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 3Health News:Insights Give New Hope Against Cystic Fibrosis 2
Thompson surgical radiotranslucent anterior lumbar retractor system....
... is the first true high-speed, high-torque touch control ... comparable to Legend Gold and runs at 73,000 ... design provides ergonomic positioning and true variable speed ... the Legend Gold Touch is also smaller, with ...
... The METRx Microdiscectomy System incorporates specially designed ... a surgical area in a minimally invasive ... diameter size from 5.3 mm to 20.8 ... inserted sequentially - one around the other ...
... System, a uniquely designed system combining ... two systems into one. Detachable blade ... site during retractor placement, providing better ... retractor body slides easily onto the ...
Medicine Products: